他克莫司联合厄贝沙坦治疗糖尿病肾病的疗效及对血清Angptl4 GDF-15 CTGF水平的影响

doi:10.3969/j.issn.1006-6233.2019.09.008

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1258 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the curative efficacy of tacrolimus combined with irbesartan in treatment of diabetic nephropathy and effects on serum angiopoietin-like protein 4 (Angptl4), growth differentiation factor-15(GDF-15) and connective tissue growth factor(CTGF) levels. Methods: 105 patients of diabetic nephropathy who received therapy from August 2016 to August 2018 in our hospital were selected as research objects, according to the random number table,those patients were divided into the 55 cases of the observation group and the 50 cases of the control group, they were received routine treatment, the control group was treated with irbesartan on the basis of the above, while the observation group was treated with tacrolimus injection on the basis of the control group, they were treated for 21 days. The changes of serum Angptl4, GDF-15, CTGF (Enzyme-linked immunosorbent assay), blood sugar, renal function and adverse reactions were observed in both groups. Results: After treatment, the serum Angptl4, GDF-15 and CTGF levels in the observation group were significantly lower than those in the control group (P＜0.05); there was no significant difference in fasting blood glucose (FBG), postprandial blood glucose (2hPG) and glycosylated hemoglobin (HbA1c) between the two groups before and after treatment (P＞0.05); the urea nitrogen (BUN), serum creatinine (SCr) and 24-hour urinary microprotein excretion rate (UAER) in the observation group were significantly lower than those in the control group (P＜0.05); there was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion: Tacrolimus combined with irbesartan is well for diabetic nephropathy, which can effectively reduce the expression of serum Angptl4, GDF-15 and CTGF, improve renal vascular function and promote the recovery of renal function, and without increasing adverse drug reactions, it has high clinical value.

Key words： Diabetic nephropathy Irbesartan Tacrolimus Serum factor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAN Wensheng
	ZHANG Yanfei
	GONG Jinqiang

Cite this article:

YAN Wensheng,ZHANG Yanfei,GONG Jinqiang. Curative Efficacy of Tacrolimus combined with Irbesartan in Treatment of Diabetic Nephropathy and Effects on Serum Angptl4 GDF-15 and CTGF Levels[J]. HeBei Med, 2019, 25(9): 1438-1442.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2019.09.008 OR http://www.hbyxzzs.cn/EN/Y2019/V25/I9/1438

[1] 杨文英.中国糖尿病的流行特点及变化趋势[J].中国科学:生命科学,2018,48(08):812~819.
[2] Nadolnik K, Skrypnik D, Skrypnik K, et al. Diabetic nephropathy in the elderly – clinical practice[J]. Rocz Panstw Zakl Hig, 2018, 69(4): 327~334.
[3] Mirhashemi SM, Rahimi F, Soleimani A, et al. Effects of omega-3 fatty acid supplementation on inflammatory cytokines and advanced glycation end products in patients with diabetic nephropathy: a randomized controlled trial[J]. Iran Kidney Dis, 2016, 10(4): 197~204.
[4] Koszegi S, Molnar A, Lenart L, et al. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition[J].Physiol, 2019, 597(1): 193~209.
[5] Chen Y, Liu P, Chen X, et al. Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy[J]. Am Med Sci, 2018, 355(5): 418~424.
[6] Mohammad KG, Idrees MK, Ali T, et al. Posttransplant diabetes mellitus among live-related kidney transplant recipients: sindh institute of urology and transplantation experience[J]. Saudi Kidney Dis Transpl, 2018, 29(6): 1320~1325.
[7] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国医学前沿杂志(电子版),2015,7(3):26~89.
[8] Ma J, Chen X, Li JS, et al. Upregulation of podocyte-secreted angiopoietin-like-4 in diabetic nephropathy[J]. Endocrine, 2015, 49(2): 373~384.
[9] Nair V, Robinson-Cohen C, Smith MR, et al. Growth differentiation factor-15 and risk of CKD progression[J].Am Soc Nephrol, 2017, 28(7): 2233~2240.
[10] Sandkovsky U, Qiu F, Kalil AC, et al. Risk factors for the development of cytomegalovirus resistance in solid organ transplantation: a retrospective case-control study[J]. Transplant Proc, 2018, 50(10): 3763~3768.
[11] El Hennawy HM, Al Hashemy A, Al Harbi N, et al. A single-center 4-year experience with 47 pediatric renal transplants: Evolving trends[J]. Saudi Kidney Dis Transpl, 2018, 29(6): 1303~1310.
[12] Anandh U, Nikalji R, Parick A. Membranous nephropathy in a patient with charcot-marie-tooth disease: association of myelin mutations[J]. Indian Nephrol, 2018, 28(5): 397~400.